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Sentinel lymph node biopsy (SLNB) has become a widely accepted standard procedure in the staging of patients with cutaneous
melanoma and absence of clinical lymph node metastases, although there is no final proof that SLNB influences overall survival in
these patients. This study investigated the accuracy of SLNB and the clinical outcome of patients after a mean follow-up of 22 months.
Between 1998 and 2003, SLNB was performed in 309 consecutive patients. Patients with one or more positive sentinel lymph nodes
(SLNs) were subjected to selective lymphadenectomy (SL). Survival analyses were performed using the Kaplan–Meier approach. A
Cox proportional-hazard analysis was used for univariate and multivariate analysis to explore the effect of variables on survival.
Sentinel lymph nodes were identified in 299 of 309 patients (success rate: 96.8%). Of these, 69 (23%) had a positive SLN. The false-
negative rate was 9.2%. Recurrence of disease to the regional lymph node basin (3.0%) and to the locoregional skin (2.6%) was rare in
SLN-negative patients in contrast to SLN-positive patients (7.2 and 17.4%, respectively). The 3-year overall survival was 93 and 83%
for SLN-negative and SLN-positive patients, respectively. Upon multivariate analysis, SLN status (Po0.001), Breslow thickness
(Po0.02) and ulceration (Po0.026) were all found to be independent prognostic factors with respect to disease-free survival,
whereas Breslow thickness proved to be the only significant factor with respect to overall survival.
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Since its introduction by Morton in 1992 (Morton et al, 1992)
sentinel lymph node biopsy (SLNB) has become a standard
procedure in the staging and treatment of primary melanoma
X1mm tumour thickness and clinically negative regional lymph
nodes. According to Morton, the sentinel lymph node (SLN) can be
defined as ‘the lymph node nearest the site of the primary
melanoma, on the direct drainage pathway’.
Primary aims of this procedure were (i) to ascertain individual
lymphatic drainage patterns of the primary tumour towards one or
more different lymph node basins and (ii) to detect patients with
micrometastatic lymphatic disease for selective lymphadenectomy
(SL), which has been beneficial at least in subsets of melanoma
patients (Balch et al, 1996).
Indeed SLN status has been found to be the strongest prognostic
factor for survival and recurrence in patients with melanoma and
clinically negative lymph nodes in a multicentre trial with 612
patients (Gershenwald et al, 1999). This observation was also taken
into account at the revision of the staging system for cutaneous
melanoma under the auspices of the American Joint Committee on
Cancer (AJCC) in 2001. They concluded that ‘the information
obtained from examining the sentinel node has an important
impact on the staging of the disease, treatment planning, and the
conduct of clinical trials in melanoma patients’ (Balch et al, 2001).
We have performed SLNB in more than 300 patients with
melanoma stage I/II, all according to the same protocol. In this
cohort of patients, we evaluated the accuracy of this procedure and
the effect of SLN status on disease-free and overall survival.
PATIENTS AND METHODS
Between 1998 and 2003, SLNB has been performed in 309
consecutive patients. All tumours were diagnosed by primary
excision with a tumour margin p0.5cm. Indications for SLNB
were Breslow tumour thickness X1mm, Clark level XIV,
ulceration and lesions with signs of regression or subungual
localisation of the primary melanoma. Before SLNB, evidence of
macrometastatic disease in regional lymph nodes or distant sites
was ruled out by physical examination and individual staging
procedures such as ultrasound, chest X-ray and computed
tomography. Patients with tumour-positive SLNs were subjected
to SL. All patients with primary melanoma X1.5mm thickness
were considered for low-dose IFNa-2b therapy and patients with
additional positive lymph nodes upon SL were considered for
adjuvant high-dose interferon therapy according to Kirkwood et al
(1996). Patient characteristics are shown in Table 1. The mean age
of patients was 55.8 years (range 18–86 years); 58% were male.
Histolopathology showed nodular (124 patients, 40%) or super-
ficial spreading melanoma (105 patients, 34%) in the majority of
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spatients. Ulceration of the primary lesion was present in
65 patients (21%). The mean tumour thickness (Breslow)
was 2.7mm (range: 0.25–30mm). Of these, five patients presented
with primary lesions ranging from 4 to 10mm and one patient
with a primary melanoma of 30mm tumour thickness.
Most patients had melanoma of Clark level IV (208 patients,
67%). Breslow tumour thickness and Clark level were not
taken into account in six patients because of regression (four
patients) or subungual localisation (two patients) of the primary
melanoma.
Lymphoscintigraphy according to Berger and Cascinelli (Berger
et al, 1997; Cascinelli et al, 2000) was performed the day before
surgery by intradermal administration of technetium-99m-labelled
nanocolloid at a dose of 30–60MBq (Nanocoll
s; Sorin Biomedica,
Saluggia, Italy) around the biopsy site. Dynamic and static images
were obtained. Under general anaesthesia methylene blue dye
(0.3–1ml) was injected intradermally around the excisional scar.
Sentinel lymph nodes were identified intraoperatively by their blue
colour and/or radioactivity detected with a hand-held gamma
probe (C-Trak
s Surgical Guidance System, Morgan Hill, CA,
USA). All blue nodes and all nodes X10% of the most radioactive
or ‘hottest’ node were considered SLNs. Subsequently, the previous
melanoma excisional biopsy scar was excised with 1 or 2cm
margin, depending on the thickness of melanoma invasion (p2
and 42mm, respectively).
Sentinel nodes were fixed in 10% neutral-buffered formalin and
embedded in paraffin. Serial 4mm thick sections (average: 10
levels) were analysed by conventional histologic staining (haema-
toxylin and eosin (H&E)) along with immunohistochemical
staining using antisera directed against the S-100 protein and the
melanoma antigen HMB-45. After SL, dissected lymph nodes were
analysed by H&E and immunohistochemistry by nonserial
sectioning.
Follow-up was performed every 3 months by physical examina-
tion. Ultrasound of lymph node basins and abdomen as well as
chest X-ray were performed every 6 months. Computed tomo-
graphy, magnetic resonance imaging and FDG-PET (fluorine-18-2-
fluoro-2-deoxy-D-glucose positron emission tomography) were
performed in patients with unclear results suggestive of metastatic
disease.
Continuous data were compared with the T-test or with the
Mann–Withney test, as appropriate. The w
2 test or Fisher’s exact
test were used for the comparison of proportions. Survival analyses
were performed according to the life tables method and according
to the method described by Kaplan and Meier. Comparison of the
survival between groups was performed with the log-rank test. A
Cox proportional-hazard analysis was used for univariate and
multivariate analysis to explore the effect of variables on survival.
The SPSS 10.0 software package (SPSS Inc., Chicago, IL, USA) was
used for all statistical analyses. All given P-values are two-tailed
and a P-value of o0.05 was regarded to indicate statistical
significance.
RESULTS
Sentinel lymph nodes were found in 299 of 309 patients (success
rate: (100–10/3.09)¼96.8%). In 10 patients, no sentinel node
could be identified by either lymphoscintigraphy or blue dye. None
of these patients was subjected to immediate lymph node
dissection. Eight patients are still alive without any sign of
continuing disease, one patient died of distant metastatic disease
without evidence of lymph node metastasis and one patient was
subjected to SL upon appearance of clinically positive lymph nodes
after a follow-up of 20 months. Sentinel nodes were identified in
one, two or three regional lymph node basins in 264 (85.4%), 30
(9.7%) and five patients (1.62%), respectively (Table 2). Among the
five patients mapped in three different lymph node basins, four
had primary melanoma in the lumbal region and one in the
Table 1 Clinical and pathologic characteristics of the melanoma patient
population (n¼309)
No. %
Sex
Female 131 42
Male 178 58
Age
Mean 55.8
Range 18–86
Site of primary tumour
Head and neck 15 5
Upper extremity 32 10
Lower extremity 74 24
Acral 24 8
Trunk 164 53
Breslow thickness (mean: 2.7mm; range: 0.25–30mm)
p1mm 41 13
1.01–2mm 139 45
2.01–4mm 80 26
44mm 43 14
Regr./subungual 6 2
Clark level
II 8 3
III 70 23
IV 208 67
V1 7 5
Regr./subungual 6 2
Ulceration
Absent 241 78
Present 66 21
Subungual 2 1
Histological subtype
Superficial spreading 105 34
Nodular 124 40
Acrolentiginous 18 6
Lentigous malignant 11 4
Desmoplastic 1 0.3
Unclassified 50 16
Table 2 Number of lymph node basins and number of SLNs at SLNB
Total %
No. of basins
1 264 85
23 0 1 0
35 2
01 0 3
No. of SLN
01 0 3
1 124 40
27 6 2 5
35 5 1 8
42 5 8
59 3
69 3
Total 309 100
SLN¼sentinel lymph node; SLNB¼sentinel lymph node biopsy.
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sscapular region. Extra-anatomic SLNs were found in 10 of 299
patients (3.2%).
In 299 patients, a total of 640 (mean¼2.1) SLNs were collected.
In almost 60% of SLNB, two or more sentinel nodes were identified
as either hot or blue (Table 2). Postoperative complications
occurred in 7% and were mostly transient including seroma/
haematoma or wound infection.
Patient characteristics stratified by SLN and SL status are shown
in Table 3. Positive SLNs were identified in 69 patients (23%).
Furthermore, seven patients developed recurrence in a lymph node
basin that was negative by SLNB. This yields a false-negative SLNB
rate of 9.2% (seven of (69þ7)) and a failure rate of 2.2% (seven of
309). Ulceration, Clark level 4II and Breslow thickness were all
significant variables on SLN status. Probability of finding a
positive SLN increased from 4% (one of 24 patients) in patients
with tumour thickness p1mm up to 50% in patients with tumour
thickness of greater than 4mm (24 of 48 patients; Po0.001).
Of 69 patients with one or more positive SLN, 67 were subjected
to SL (two patients refused further surgical treatment). Among the
67 patients with one or more metastatic SLN, 14 (21%) were found
to bear further metastases in non-SLNs in the dissected basin upon
SL. The median tumour thickness in these patients was 3.1mm
compared to 3.0mm in patients with positive SLN only (NS,
P¼0.88) and 1.6mm in SLN-negative patients (Po0.001).
Positive SLN specimens were histologically subdivided by
bearing micro- (o2mm in diameter) or macrometastastatic
disease according to Carlson (Carlson et al, 2003; Table 4). Micro-
metastasis in the SLN was found in 47 (68%) and macrometastasis
in 22 (32%) of 69 patients. In the group of micrometastatic positive
SLN, seven (15%) out of 47 patients presented with further
metastases in the same lymph node basin after SL, compared to
seven (27%) of 22 patients with macroscopically positive SLNs
(NS; P¼0.26).
Of 309 patients, 49 (15.9%) developed disease recurrence during
follow-up (Table 5). The median time to progression of disease was
18 months. In the group of patients with a positive SLN, 25 (36.2%)
out of 69 patients developed recurrence: 12 (17.4%) to the
locoregional skin, five (7.2%) to the draining lymph node basin
and eight (11.6%) to systemic sites. In patients with a negative SLN
finding, 22 (9.5%) developed recurrence: six (2.6%) patients to the
locoregional skin, seven (3.0%) to the draining lymph node basin
and nine (3.9%) to systemic sites.
To date, 20 (6.5%) out of the 309 patients have died of
metastatic disease. Of these, nine (3.9%, nine of 230)
had a negative SLN, nine (13%, nine of 69) had a positive SLN
and two (20%, two of 10) patients had an unknown sentinel
node status. The 3-year overall and disease-free survival of the
entire group of melanoma patients computed from the date
of excision of the primary lesion were 90 and 75%, respectively.
By univariate analysis, patients with a negative SLN had a
significantly better disease-free (Po0.001) and overall survival
(Po0.047) than patients with a positive SLN (Figure 1): The
3-year disease-free survival for negative and positive SLN
patients was 82 and 55%, respectively. The 3-year overall survival
for negative and positive SLN patients was 93 and 83%,
respectively.
Table 3 Patient characteristics stratified by SLN status and SL status
All patients SLN negative SLN positive SLN and SL positive
No. of patients % No. of patients % No. of patients % No. of patients %
Total 299 100 230 77 69 23 14 20
Sex
Male 171 57 126 74 45 26 10 22
Female 128 43 104 81 24 19 4 17
Site of primary tumour
Trunk 158 53 120 76 38 24 7 18
Clark level
II 8 3 8 100 0 0 0 0
III 71 24 59 83 12 17 1 8
IV 202 67 151 75 51 25 13 25
V1 2 4 6 5 0 6 5 0 0 0
Regr./subungual 6 2 6 100 0 0 0 0
Ulceration
Absent 226 76 180 80 46 20 9 20
Present 67 22 44 66 23 34 5 22
Regr./subungual 6 2 6 100 0 0 0 0
Tumour thickness (mm)
p1 24 8 23 96 1 4 0 0
1.01–2 129 43 109 84 20 16 2 10
2.01–4 92 31 68 74 24 26 9 38
44 4 81 62 45 0 2 4 5 0 3 1 3
Regr./subungual 6 2 6 100 0 0 0 0
SLN¼sentinel lymph node; SL¼selective lymphadenectomy.
Table 4 Distribution of patients according to SL status and positive SLN
status
SLN-positive patients (n¼69)
SL Micrometastatic Macrometastatic
Negative 38 81% 15 73%
Positive 7 15% 7 27%
Not done 2 4% 0 0%
SLN¼sentinel lymph node; SL¼selective lymphadenectomy.
SLNB status in melanoma patients
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sThe model selected for multivariate regression was created by
the forward stepwise elimination method. Analysis of several well-
known prognostic factors with respect to disease-free survival are
shown in Table 6: Positive SLN status (Po0.001), presence of
ulceration (P¼0.026) and Breslow tumour thickness (P¼0.02)
were all statistically significant prognostic factors by multivariate
analysis, whereas Breslow thickness proved to be the only
statistically significant prognostic factor with respect to overall
survival (P¼0.002).
DISCUSSION
Since the first reports on SLNB for stage I and II melanoma lesions
appeared, there has been an overwhelming enthusiasm for this
technique. Several published series have shown various kinds of
methods for identification, pathological examination and selection
criteria for patients who could profit most from this staging
method.
In our study, one or more SLNs were identified in 299 of 309
(96.8%) patients. As we did not perform synchronous SLNB and
elective lymphadenectomy, false-negative rate of SLNB can only be
estimated by recurrence of metastatic disease in the draining
lymph node basin. Out of 209 patients with a negative SLN finding,
seven patients (3.0%) developed a nodal recurrence in the
previously mapped basin upon follow-up. One additional patient
presented with metastases in the groin after being mapped in the
ipsilateral axillary region. This yields a false-negative sentinel rate
of 9.2% and a failure rate of 2.2%, which is in accordance with
previous studies (Gershenwald et al, 1999; Morton et al, 1999;
Morton et al, 2003; Vuylsteke et al, 2003). As previously shown by
Gershenwald, detection failure of positive SLNs most commonly
occurs because conventional histologic evaluation is unable to
identify occult metastatic disease (Gershenwald et al, 1998).
Furthermore, Morton reported a statistical lack in the detection
of a positive SLN in patients with primary melanoma o2.01mm:
Compared to the incidence of regional lymph node metastasis in a
historical control group of patients who where treated by wide
local excision only (WLE), incidence of a positive SLN is only 60%.
In contrast, this procedure is shown to detect accurately
metastases from thicker lesions. New methods of sentinel node
labelling, reflecting the microanatomy of the lymph node by the
use of carbon dye, could decrease the false-negative rate of SLNB
(Morton et al, 2003). The molecular analysis of the SLN using
reverse transcription-polymerase chain reaction (RT–PCR) has
Table 5 First site of recurrence and death of disease
Locoregional skin Draining LN basin Systemic Total recurrence Death of disease
SLN neg (n¼230) 6 (2.6%) 7 (3.0%) 9 (3.9%) 22 (9.5%) 9 (3.9%)
SLN pos (n¼69) 12 (17.4%) 5 (7.2%) 8 (11.6%) 25 (36.2%) 9 (13.0%)
SLN unknown (n¼10) 0 (0%) 1 (10.0%) 1 (10.0%) 2 (20.0%) 2 (20.0%)
Total 18 (5.8%) 13 (4.2%) 18 (5.8%) 49 (15.8%) 20 (6.5%)
SLN¼sentinel lymph node; LN¼lymph node.
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Figure 1 Kaplan–Meier curves for overall (left panel) and disease-free (right panel) survival for patients undergoing successful SLNB. The 3-year disease-
free survival was 82% and 55% for negative and positive SLN patients, respectively. The 3-year overall survival was 93 and 83% for negative and positive SLN
patients, respectively.
Table 6 Multivariate analysis of prognostic variables influencing disease-
free and overall survival
Disease-free survival Overall survival
P HR 95% CI P HR 95% CI
Tumour thickness o0.001 1.067 1.010–1.127 0.002 1.098 1.036–1.165
Ulceration 0.003 2.230 1.103–4.509
SLN status o0.001 4.264 2.216–8.205
HR¼hazard ratio; CI¼confidence interval.
SLNB status in melanoma patients
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sbeen found to upstage a significant portion of SLN-negative
patients. Since this method does not discriminate between
melanoma metastases and nodal nevi, further investigations are
needed until this procedure will become the standard of care.
Nevertheless, there is evidence that mechanisms other than
failure of histopathologic examination may contribute to the
failure of the SLNB technique in some patients. Li re-examined
negative SLN specimens again and later of patients with regional
recurrence and identified metastases in only seven of 12 false-
negative SLNs in a group of 1152 patients (Li et al, 2003).
In our study, 20% of patients with positive SLN were found to
have additional lymph node metastasis upon SL. Whether elective
lymph node dissection is able to improve overall survival is still a
matter of debate. In a single study, early detection of occult
metastatic disease in the draining lymph node basin by elective
(prophylactic) lymph node dissection has been shown to increase
survival when compared to therapeutic (delayed) lymph node
dissection (Cascinelli et al, 1998). On the other hand, Veronesi
presented a prospective randomized clinical trial conducted by the
WHO in which patients with melanoma of the limb did not benefit
from prophylactic lymph node dissection (Veronesi et al, 1982).
This study was further supported by Sim, who also observed no
significant difference with respect to overall survival and
metastasis-free survival when patients were split into three
different groups treated with WLE alone, WLE and ‘immediate
lymphadenectomy’, or WLE and ‘delayed lymphadenectomy’ (Sim
et al, 1986). Nevertheless, 30% of patients with melanoma stage III
survive more than 15 years after therapeutic lymphadenectomy
(Balch et al, 2001), but this may not be addressed by surgical
removal of lymph node metastases alone.
In our study, 15.9% of all patients developed recurrence of
disease. Within a median follow-up of 22 months recurrence rate
for SLN-positive patients (36.2%) was significantly higher
compared to SLN-negative patients (9.5%). Several studies have
addressed recurrence of disease for SLN-negative and -positive
patients and showed comparable results, depending on the median
follow-up period (Table 7).
Pattern of recurrence for SLN-negative patients reflects previous
observations (Statius Muller et al, 2002), where relapse in the
previously mapped lymph node basin is rare and equally as
frequent as systemic metastasis. In contrast, systemic metastasis
occurs in 11.6% of SLN-positive patients; however, the most
frequent site of relapse in these patients was the locoregional skin
(17.4%). Estourgie also found a substantially higher rate of local/
in-transit metastases in SLN-positive patients compared to SLN-
negative patients (23 and 7%, respectively). They suggested that
this potentially inherent risk of the SLNB should be weighed
against the possible survival benefit of early removal of nodal
metastases (Estourgie et al, 2003). A possible explanation for high
local recurrence rates in SLN-positive patients in our study may be
excision margins of only 1 or 2cm for primary melanoma below or
above 1.5mm in tumour thickness, respectively. As shown by
Thomas, 1-cm margin of excision for melanoma with a poor
prognosis (as defined by a tumour thickness of at least 2mm) is
associated with a significantly greater risk of locoregional
recurrence than is a 3-cm margin. Nevertheless, overall survival
was similar in the two groups (Thomas et al, 2004). Additionally,
there might exist an inherent iatrogenic risk of SLNB and SL in
SLN-positive patients: As described by Thomas and Clark (2004),
patients having SLNB have approximately double the incidence of
local/in-transit recurrence, while SLN-positive patients having SL
have greater than four times the expected incidence.
In our series, 3-year disease-free and overall survival rates were
75.0 and 90.4%, respectively. Upon multivariate analysis, tumour
thickness, ulceration and SLN status were all found to be
significant factors with respect to disease-free survival. With
respect to the overall survival upon multivariate analysis, tumour
thickness was the only significant factor, and neither SLN status
nor ulceration. This could be explained in part by the short follow-
up period of our study. In contrast to this assumption, two other
studies by Nowecki and Cascinelli with similar follow-up periods
of 34 and 29 months, respectively, all showed a significant impact
of SLN status on overall survival upon multivariate analysis
(Cascinelli et al, 2000; Nowecki et al, 2003). Furthermore, Meier
demonstrated that distant metastasis in patients with prior
metastasis to lymph nodes already evolves after a median follow-
up period of 25 months (Meier et al, 2002).
An alternative explanation for this finding could be that the
patient characteristics in our study group differ from other studies
as 3-year overall survival for SLN-positive patients was substan-
tially higher in our study if compared to Gershenwald et al (1999)
(83 vs 69.9%). This is not the case as the median tumour thickness
of SLN-positive patients was identical in both studies (3.0mm).
Likewise, neither percentage of ulcerated tumours nor number of
positive lymph nodes were substantially different from our study.
In conclusion, our study, including more than 300 patients,
supports the influence of SLNB on disease-free survival, and is in
accordance with previous studies in demonstrating the impact of
tumour thickness, ulceration of the primary tumour and Clark
level 42 on the occurrence of positive SLNs. In contrast to
previous studies, no statistically significant correlation between
SLN status and overall survival was observed in our study
population.
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